Physician profile
John Kellum
NPI 1255326989
$3,691.91
in general payments reported to CMS, 2019-2025
37 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $515 · 2021: $711 · 2022: $820 · 2023: $488 · 2024: $302 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,089.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $966.07 | 2019-2025 | |
| Exeltis, USA INC. | $466.81 | 2019-2025 | Slynd |
| Galderma Laboratories, L.P. | $250.83 | 2019-2022 | |
| Allergan, INC. | $237.54 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $166.14 | 2023-2024 | Myfembree, Gemtesa |
| Myovant Sciences INC. | $130.25 | 2022 | |
| Pfizer INC. | $125.11 | 2019-2024 | |
| Avion Pharmaceuticals | $112.62 | 2020-2023 | Balcoltra |
| Intuitive Surgical, INC. | $110.79 | 2025 | |
| Mayne Pharma Commercial LLC | $99.58 | 2022-2024 | |
| Astellas Pharma US INC | $85.48 | 2023-2024 | Veozah |
| Agile Therapeutics, INC. | $85.39 | 2021-2022 | |
| Therapeuticsmd, INC. | $74.78 | 2020-2022 | |
| Lsi Solutions INC | $66.80 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.31 | 2024-2025 | Caplyta |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $59.66 | 2019-2020 | |
| Abiomed | $51.32 | 2022 | |
| Gynesonics, INC. | $44.94 | 2022 | |
| Organon LLC | $42.73 | 2022-2023 | Nexplanon |
| Axsome Therapeutics, INC. | $39.07 | 2023 | Auvelity |
| Scynexis, INC. | $37.70 | 2022 | |
| Biogen, INC. | $36.94 | 2025 | Zurzuvae |
| Shield Therapeutics INC | $36.14 | 2022-2025 | |
| Evofem Biosciences, INC. | $33.77 | 2020-2024 | |
| Coopersurgical, INC. | $32.48 | 2020-2023 | Endosee |
| Lupin INC. | $29.51 | 2020 | |
| Avanos Medical | $25.48 | 2019 | |
| Dilon Technologies, INC. | $22.87 | 2025 | Hemoblast Bellows |
| Acessa Health INC. | $22.69 | 2019 | |
| Baxter Healthcare | $22.55 | 2022 | |
| Becton, Dickinson and Company | $21.05 | 2023 | Bd Onclarity |
| Novo Nordisk INC | $19.59 | 2023 | Wegovy |
| Azurity Pharmaceuticals, INC. | $18.64 | 2025 | Edarbi |
| Mission Pharmacal Company | $16.44 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $13.68 | 2019 | |
| Merck Sharp & Dohme LLC | $12.02 | 2019 | |
| Aspira Women'S Health INC | $11.14 | 2024 | Ova1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kellum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.